Back to search

Georgia Institute of Technology

Mesenchymal stem cell therapies for the trabecular meshwork in glaucoma

Abstract

dc:description.abstract

Glaucoma, a leading cause of blindness, affects over 70 million people worldwide, and its incidence is expected to continue to rise with an aging population. The exact origin for primary open angle glaucoma (POAG), the most prevalent form of glaucoma, is unknown, but an increased intraocular pressure (IOP) is a well-established risk factor for POAG. IOP is largely determined by aqueous humor production rate and outflow through drainage tissues in the anterior eye, specifically through the trabecular meshwork. In POAG, the cellularity of the trabecular meshwork (TM) is significantly decreased in comparison to healthy eyes, which presumably leads to loss of TM function, higher outflow resistance and, thus, increased IOP. As a result, therapies striving to restore TM cellularity could alter glaucoma progression. This research will investigate the use of mesenchymal stem cells (MSCs) to restore trabecular meshwork function. MSC therapies represent a new, largely unstudied, therapeutic approach for the TM, and, as such, methods and procedures for assessing differentiation, delivering cells to the eye, and assessing these cells’ therapeutic potential for POAG are not yet established. The overall objective of this thesis was to develop solutions to these essential first steps so that MSC therapies can be properly assessed and implemented. We first established methods to characterize differences between MSCs and TM cells at the RNA, protein, and functional levels for assaying MSC differentiation. For studying delivery of MSCs to the eye, we implemented an ultrasound and photoacoustic imaging platform for tracking MSC delivery to the TM in real time. Next, magnetic nanoparticles were used to label and steer MSC to the TM at high efficiency and uniformity compared to passive delivery approaches. Lastly, an improved ex vivo model of POAG was developed to properly mimic glaucomatous changes in the TM triggered by oxidative stress-induced damage. Overall, this thesis established methods and procedures needed for developing MSC therapies for POAG. Our results allow MSC differentiation to be properly characterized, MSC location to be monitored in real-time in the eye, MSC delivery to be improved with magnetic nanoparticles, and MSC therapeutic benefit to be assessed using a suitable ex vivo model. Future work should assess the potential of MSCs for refunctionalizing the TM as a novel POAG therapy.

Degree

thesis:*
Level thesis:degree_level
Doctoral
Department dc:contributor.department
Biomedical Engineering (Joint GT/Emory Department)
Grantor dc:publisher
Georgia Institute of Technology
Year dc:date.issued
2018

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Snider, Eric Joseph
Advisor dc:contributor.advisor
  • Ethier, C. Ross
Committee members dc:contributor.committeemember
  • Garcia, Andres
  • Prausnitz, Mark
  • Stamer, W. Daniel
  • Xu, Chunhui

Subjects

dc:subject × 6

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/1853/59825

Chain of custody

source
Harvested from
Georgia Tech
Base URL
repository.gatech.edu/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Snider, Eric Joseph. Mesenchymal stem cell therapies for the trabecular meshwork in glaucoma. Doctoral thesis, Georgia Institute of Technology, 2018. http://hdl.handle.net/1853/59825